Abeona Therapeutics

Intangible assets: Strong for a niche.

Zevaskyn is the first and only FDA‑approved autologous cell‑sheet gene therapy for RDEB wounds, protected by data exclusivity for biologics, orphan designation benefits, method and device‑related IP (e.g., packaging/transport patent to mid‑2040), plus proprietary manufacturing know‑how at the Elisa Linton Center (Cleveland).

However, orphan exclusivity does not block different modalities (e.g., HSV‑based Vyjuvek), so differentiation must rest on outcomes, durability and logistics. Score: 70. Switching costs: High at the treated‑wound level.

An autologous, surgical, one‑time application per wound creates substantial switching frictions post‑treatment; the care pathway involves biopsy, individualized manufacture, and grafting, supported by QTCs and Abeona Assist. Score: 85. Network effects: Minimal; referral networks can help but do not create classic two‑sided dynamics.

Score: 10. Cost advantage: Moderate. In‑house cGMP for both retroviral vector and cell‑sheets can lower COGS over time and improve reliability, but scale is capped by the small TAM and individualized processing. Score: 45. Efficient scale: Present. A very small U.S.

RDEB population (≈1.35/million) limits the number of viable entrants and supports a concentrated, center‑based model.

Score: 60. Weighted view: Multiple but fragile moats anchored in manufacturing know‑how, specialized centers and care pathway complexity; durability depends on flawless quality systems and continued clinical differentiation versus repeat‑dose competitors.